scholarly journals Impact of Preoperative Serum Tumor Markers in Patients with Lung Squamous Cell Carcinoma

2021 ◽  
Vol 10 (03) ◽  
pp. 48-55
Author(s):  
Masaki Tomita ◽  
Shoei Kuroki ◽  
Tomoka Hamahiro ◽  
Ryo Maeda ◽  
Takanori Ayabe
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Markers ◽  
Squamous Cell ◽  
Lung Squamous Cell Carcinoma ◽  
Serum Tumor Markers ◽  
Preoperative Serum

The usefulness of new serum tumor markers in head and neck squamous cell carcinoma

2009 ◽  
Vol 140 (3) ◽  
pp. 375-380 ◽  
Author(s):  
César Álvarez Marcos ◽  
Daniel Al Kassam Martínez ◽  
Juan Ramón de los Toyos ◽  
Francisco Domínguez Iglesias ◽  
Mario Hermsen ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Tumor Markers ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma ◽  
Serum Tumor Markers

Correlation between serum tumor markers, tissue proliferative activity, and clinicopathologic factors in patients with locally advanced esophageal squamous cell carcinoma.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14639-e14639
Author(s):  
Somkiat Sunpaweravong ◽  
Patrapim Sunpaweravong ◽  
Puttisak Puttawibul ◽  
Pleumjit Boonyaphiphat ◽  
Anupong Nitiruangjaras
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Markers ◽  
Squamous Cell ◽  
Proliferative Activity ◽  
Locally Advanced ◽  
Clinicopathological Factors ◽  
Ki 67 ◽  
Serum Tumor Markers

e14639 Background: Squamous cell carcinoma antigen (SCCA) and CYFRA 21-1 have been reported as useful tumor markers for esophageal squamous cell carcinoma (ESCC), but no information has yet been reported about the relationship between these serum tumor markers and tissue proliferative activity (Ki-67). The aim of this study was to compare SCCA, CYFRA 21-1 and Ki-67 with clinicopathological factors and survival in locally advanced ESCC patients. Methods: Pre-treatment SCCA and CYFRA 21-1 serum levels were measured by enzyme-linked immunoassays while the expression of tissue Ki-67 activity was calculated by immunohistochemical nuclear staining on paraffin-embedded tumor samples of locally advanced ESCC patients. The association between these biomarkers, clinicopathological factors, and overall survival were analyzed by Cox proportional hazards model. Results: 166 locally advanced ESCC patients from our institution (2002-6) were evaluated. Their median age was 62 years (39-90), M:F 144:22, location of tumor (upper:middle:lower 31:83:53) and histological grade (well:moderate:poor 50:73:43). 43% had received surgery, 22% chemoradiation and 35% best supportive care. Follow-up times ranged from 2 months to 38 months, and the median survival was 11.0 months. Elevated SCCA (>1.5 ng/mL) and CYFRA 21-1 (>3.5 ng/mL) before treatment were found in 79.1% and 50.4% of the patients, respectively, while 42.6% had both serum markers elevated. The SCCA and CYFRA 21-1 levels were not correlated (p=0.128) to each other, nor either to age, sex, T, N, M, location, grade or Ki-67. High Ki-67 expression levels were significantly correlated with T4 (p=0.010), M1 (p=0.010) and poor grade (p=0.015) but not to age, sex, N or location. Levels of SCCA, CYFRA 21-1 and Ki-67, alone or in any combination, were not correlated to survival of patients. Conclusions: This study suggests that the evaluation of SCCA and CYFRA 21-1 are of no particular correlation to clinicopathological factors and survival in locally advanced ESCC, but Ki-67 is correlated with T, M and grade.

PD-1 and PD-L1 Related Comprehensive Analysis of Lung Squamous Cell Carcinoma

2018 ◽  
Author(s):  
Guoping Li ◽  
Junyi Wang ◽  
Xi Dai ◽  
Dehong Wu ◽  
Xiang He ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Lung Squamous Cell Carcinoma ◽  
Comprehensive Analysis

Investigation of Targeting Relationship between Micro-Rna-22 and Vegfr3 in Lung Squamous Cell Carcinoma

2020 ◽  
Vol 23 ◽  
Author(s):  
Zheng Dong ◽  
Qing-Hua Xu ◽  
Yuan-Bin Zhu ◽  
Yong-Feng Wang ◽  
Jie Xiong ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Lung Squamous Cell Carcinoma ◽  
Luciferase Reporter ◽  
Control Group ◽  
Vascular Endothelial ◽  
Luciferase Reporter Gene ◽  
Endothelial Growth Factor

Aims : The present study explored the clinical significance of microRNA-22 (miR-22) expression in lung squamous cell carcinoma and to explore the targeting relationship with vascular endothelial growth factor receptor 3 (VEGFR3). Methods: A total of 49 patients with lung squamous cell carcinoma who underwent surgical treatment was selected. The expression of miR-22 was detected by fluorescence quantitative real-time PCR (qPCR), the expression of VEGFR3 was detected by Western blotting assays, and D240 labeled microlymphatic vessels density (MLVD) was detected immunohistochemistry (IHC). Lung squamous cell carcinoma cell line SK-MES-1 was selected and the targeting relationship between miR-22 and VEGFR3 was analyzed by double luciferase reporter gene assay. Western blotting assays were used to detect the expression of vascular endothelial growth factor-D (VEGF-D) and D240 in the blank control group, empty vector transfection group, miR-22 transfection group, miR-22 and VEGFR3 co-transfection group. Results: The expression range of miR-22 in lung squamous cell carcinoma was 0.8-3.5. The expression of miR-22 in lung squamous cell carcinoma was significantly different by tumor maximum diameter, lymph node metastasis, vascular invasion and TNM stage. The expression of miR-22 was linked to survival time. There was a negative correlation between miR-22 and VEGFR3, miR-22 and MLVD. Double luciferase reporter gene assays showed that miR-22 reduced the luciferase activity of pGL3-VEGFR3-WT transfected cells. Compared with the control group, the expression of VEGF-D and D2-40 in the miR-22 transfection group was significantly decreased. However, VEGF-D and D240 in the miR-22 and VEGFR3 cotransfection group reversed the changes. Conclusion: We assumed that the abnormal expression of miR-22 in lung squamous cell carcinoma may be involved in the development and progression of lung squamous cell carcinoma. MiR-22 negatively regulated the target gene VEGFR3 to mediate lymphangiogenesis. The expression of miR-22 may also be linked to the prognosis of the disease.

scholarly journals Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents

Oncotarget ◽  
2016 ◽  
Vol 8 (12) ◽  
pp. 18885-18900 ◽  
Author(s):  
Donghai Xiong ◽  
Jing Pan ◽  
Qi Zhang ◽  
Eva Szabo ◽  
Mark Steven Miller ◽  
...  
Keyword(s):  
Gene Expression ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Lung Squamous Cell Carcinoma ◽  
Mouse Lung ◽  
Chemopreventive Agents ◽  
Gene Expression Signatures

scholarly journals Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Qi-Fan Yang ◽  
Di Wu ◽  
Jian Wang ◽  
Li Ba ◽  
Chen Tian ◽  
...  
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Prognostic Model ◽  
Lung Squamous Cell Carcinoma ◽  
Risk Groups ◽  
Stage I ◽  
Tissue Samples ◽  
Mutation Burden

AbstractLung squamous cell carcinoma (LUSC) possesses a poor prognosis even for stages I–III resected patients. Reliable prognostic biomarkers that can stratify and predict clinical outcomes for stage I–III resected LUSC patients are urgently needed. Based on gene expression of LUSC tissue samples from five public datasets, consisting of 687 cases, we developed an immune-related prognostic model (IPM) according to immune genes from ImmPort database. Then, we comprehensively analyzed the immune microenvironment and mutation burden that are significantly associated with this model. According to the IPM, patients were stratified into high- and low-risk groups with markedly distinct survival benefits. We found that patients with high immune risk possessed a higher proportion of immunosuppressive cells such as macrophages M0, and presented higher expression of CD47, CD73, SIRPA, and TIM-3. Moreover, When further stratified based on the tumor mutation burden (TMB) and risk score, patients with high TMB and low immune risk had a remarkable prolonged overall survival compared to patients with low TMB and high immune risk. Finally, a nomogram combing the IPM with clinical factors was established to provide a more precise evaluation of prognosis. The proposed immune relevant model is a promising biomarker for predicting overall survival in stage I–III LUSC. Thus, it may shed light on identifying patient subset at high risk of adverse prognosis from an immunological perspective.

scholarly journals A glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Guichuan Huang ◽  
Jing Zhang ◽  
Ling Gong ◽  
Yi Huang ◽  
Daishun Liu
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Risk Score ◽  
Squamous Cell ◽  
Cox Regression ◽  
Lung Squamous Cell Carcinoma ◽  
Gene Signature ◽  
Gene Set Enrichment Analysis ◽  
Related Gene ◽  
Cox Regression Analysis

Abstract Background Lung cancer is one of the most lethal and most prevalent malignant tumors worldwide, and lung squamous cell carcinoma (LUSC) is one of the major histological subtypes. Although numerous biomarkers have been found to be associated with prognosis in LUSC, the prediction effect of a single gene biomarker is insufficient, especially for glycolysis-related genes. Therefore, we aimed to develop a novel glycolysis-related gene signature to predict survival in patients with LUSC. Methods The mRNA expression files and LUSC clinical information were obtained from The Cancer Genome Atlas (TCGA) dataset. Results Based on Gene Set Enrichment Analysis (GSEA), we found 5 glycolysis-related gene sets that were significantly enriched in LUSC tissues. Univariate and multivariate Cox proportional regression models were performed to choose prognostic-related gene signatures. Based on a Cox proportional regression model, a risk score for a three-gene signature (HKDC1, ALDH7A1, and MDH1) was established to divide patients into high-risk and low-risk subgroups. Multivariate Cox regression analysis indicated that the risk score for this three-gene signature can be used as an independent prognostic indicator in LUSC. Additionally, based on the cBioPortal database, the rate of genomic alterations in the HKDC1, ALDH7A1, and MDH1 genes were 1.9, 1.1, and 5% in LUSC patients, respectively. Conclusion A glycolysis-based three-gene signature could serve as a novel biomarker in predicting the prognosis of patients with LUSC and it also provides additional gene targets that can be used to cure LUSC patients.

Sign in / Sign up

Export Citation Format

Share Document